Oncotarget

Research Papers:

Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model

Thinzar M. Lwin _, Kentaro Miyake, Takashi Murakami, Jonathan C. DeLong, Siamak Amirfakhri, Filemoni Filemoni, Sang Nam Yoon, Paul J. Yazaki, John E. Shivley, Brian Datnow, Bryan M. Clary, Robert M. Hoffman and Michael Bouvet

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:37333-37342. https://doi.org/10.18632/oncotarget.26484

Metrics: PDF 1282 views  |   HTML 2147 views  |   ?  


Abstract

Thinzar M. Lwin1, Kentaro Miyake1,2,3, Takashi Murakami1,2,3, Jonathan C. DeLong1, Siamak Amirfakhri4, Filemoni Filemoni4, Sang Nam Yoon1,2, Paul J. Yazaki5, John E. Shivley5, Brian Datnow6, Bryan M. Clary1, Robert M. Hoffman1,2,4 and Michael Bouvet1,4

1Department of Surgery, University of California San Diego, San Diego, CA, USA

2AntiCancer, Inc., San Diego, CA, USA

3Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan

4VA San Diego Healthcare System, San Diego, CA, USA

5Department of Molecular Imaging and Therapy, City of Hope, Duarte, CA, USA

6Department of Pathology, University of California San Diego, San Diego, CA, USA

Correspondence to:

Michael Bouvet, email: [email protected]

Keywords: fluorescence-guided surgery; LICOR IRDye800CW; anti-CEA antibody; patient derived orthotopic xenograft model; pancreatic cancer

Received: July 05, 2018     Accepted: December 04, 2018     Published: December 18, 2018

ABSTRACT

Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26484